Clinical Trials and Novel Pathogens: Lessons Learned from SARS
- 1 March 2004
- journal article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 10 (3) , 389-394
Abstract
During the recent global outbreak of severe acute respiratory syndrome (SARS), thousands of patients received treatments of uncertain efficacy and known toxicity such as ribavirin and corticosteroids. Despite this, no controlled clinical trials assessing the efficacy of these agents were conducted. If a second global SARS outbreak occurred, clinicians would not have controlled data on which to base therapeutic decisions. We discuss the unique methodologic and logistical challenges faced by researchers who attempt to conduct controlled trials of therapeutic agents during an outbreak of a novel or unknown infectious pathogen. We draw upon our own experience in attempting to conduct a randomized controlled trial (trial) of ribavirin therapy for SARS and discuss the lessons learned. Strategies to facilitate future clinical trials during outbreaks of unknown or novel pathogens are also presented.Keywords
This publication has 16 references indexed in Scilit:
- Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory SyndromeNew England Journal of Medicine, 2003
- A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong KongNew England Journal of Medicine, 2003
- Identification of Severe Acute Respiratory Syndrome in CanadaNew England Journal of Medicine, 2003
- Development of a standard treatment protocol for severe acute respiratory syndromeThe Lancet, 2003
- Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective studyThe Lancet, 2003
- Severe acute respiratory syndrome (SARS) and coronavirus testing--United States, 2003.2003
- Coronavirus as a possible cause of severe acute respiratory syndromeThe Lancet, 2003
- Hemorrhagic Fever Viruses as Biological WeaponsJAMA, 2002
- The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagenNature Medicine, 2000
- The Accuracy of Patient History, Wheezing, and Laryngeal Measurements in Diagnosing Obstructive Airway DiseaseJAMA, 2000